OATD-01 is under clinical development by Molecure and currently in Phase II for Pulmonary Sarcoidosis. According to GlobalData, Phase II drugs for Pulmonary Sarcoidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OATD-01 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OATD-01 overview
GLPG-4716 is under development for the treatment of asthma, pulmonary sarcoidosis and interstitial lung diseases/idiopathic pulmonary fibrosis. The drug candidate is administered through oral route. The drug candidate acts by targeting acidic mammalian chitinase (AMCase) and chitotriosidase-1 (CHIT1). It was also under development for the treatment of inflammatory bowel disease.
Molecure overview
Molecure is a clinical-stage biopharmaceutical company that discovers, develops and commercialization of therapeutics for cancer and respiratory diseases. The company’s lead clinical candidate OATD-01 is an inhibitor of chitinases that are being developed to treat multiple lung diseases including idiopathic pulmonary fibrosis, asthma and sarcoidosis. It is also developing CHIT-1 and YKL-40, USP7, USP21 and OATD-02 for glioblastoma multiforme (GBM), immunoOncology and other cancers. The company works in collaboration with academics, research institutions and contract research organizations for drug discovery and development. Molecure is headquartered in Warsaw, Masovia, Poland.
For a complete picture of OATD-01’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
